Submitted for Publication: April 2, 2012; final revision received June 13, 2012; accepted June 20, 2012.
Published Online: January 2, 2013. doi:10.1001/jamapsychiatry.2013.286
Conflict of Interest Disclosures: Dr IsHak received research support unrelated to the subject of this article from the National Alliance for Research on Schizophrenia and Depression (quality of life in major depression) and Pfizer (ziprasidone as monotherapy for major depression) that ended on December 31, 2011.
Funding/Support: This study was supported by grant N01MH90003 from the National Institute of Mental Health to the University of Texas Southwestern Medical Center.
Disclaimer: This article reflects the views of the authors and may not reflect the opinions or views of the STAR*D Study Investigators or the National Institutes of Health.
Additional Information: The data used in the preparation of this article were obtained from the limited access data sets distributed from the National Institutes of Health–supported Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which focused on nonpsychotic major depressive disorder in adults seen in outpatient settings. The primary purpose of this research study was to determine which treatments worked best if the first treatment with medication did not produce an acceptable response.
Additional Contributions: Lev Gertsik, MD, Russell Poland, PhD, and Asbasia Mikhail, MD, contributed significantly to the original concepts highlighted in this article. Tammy Saah, MD, Hala Fakhry, MD, Shakiba Mobaraki, MD, A. John Rush, MD, Jennice Vilhauer, PhD, Mark H. Rapaport, MD, and Andrew Leon, PhD, provided valuable feedback about the concept implementation. Debates led by Peter Whybrow, MD, Ian Cook, MD, and James Spar, MD, contributed significantly to polishing the content of this article. We thank the editors and peer reviewers of the American Journal of Psychiatry and the Administration and Policy in Mental Health and Mental Health Services Research, and we express deep appreciation for the editor and peer reviewers of JAMA Psychiatry for their outstanding review and guidance.